MCID: INT070
MIFTS: 57

Intestinal Obstruction

Categories: Fetal diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Intestinal Obstruction

MalaCards integrated aliases for Intestinal Obstruction:

Name: Intestinal Obstruction 12 29 54 6 42 44 15 70

Classifications:



External Ids:

Disease Ontology 12 DOID:8437
ICD9CM 34 560.9
MeSH 44 D007415
NCIt 50 C9175
SNOMED-CT 67 81060008
ICD10 32 K56.609 P76.2
UMLS 70 C0021843

Summaries for Intestinal Obstruction

MedlinePlus : 42 An intestinal obstruction occurs when food or stool cannot move through the intestines. The obstruction can be complete or partial. There are many causes. The most common are adhesions, hernias, cancers, and certain medicines. Symptoms include Severe abdominal pain or cramping Vomiting Bloating Loud bowel sounds Swelling of the abdomen Inability to pass gas Constipation A complete intestinal obstruction is a medical emergency. It often requires surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Intestinal Obstruction is related to ileus and hypoganglionosis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Intestinal Obstruction is SLC26A3 (Solute Carrier Family 26 Member 3). The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include colon, small intestine and pancreas, and related phenotypes are behavior/neurological and cellular

Related Diseases for Intestinal Obstruction

Diseases in the Intestinal Obstruction family:

Intestinal Pseudo-Obstruction

Diseases related to Intestinal Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 727)
# Related Disease Score Top Affiliating Genes
1 ileus 32.4 GUCY2C CRP CFTR
2 hypoganglionosis 32.2 RET GDNF ACHE
3 hirschsprung disease 1 32.1 RET NRTN GDNF EDNRB EDN3 ACHE
4 intestinal pseudo-obstruction 31.8 SGO1 RET FLNA EDNRB EDN3 CFTR
5 meckel diverticulum 31.7 KRT7 CRP CDX2
6 constipation 31.0 RET NRTN GUCY2C GDNF FLNA EDNRB
7 intestinal perforation 30.9 NOD2 KRT7 CRP
8 teratoma 30.7 KRT7 KRT20 GATA4 CDX2
9 pseudomyxoma peritonei 30.7 KRT7 KRT20 CDX2
10 diarrhea 30.7 SLC26A3 NOD2 GUCY2C CFTR
11 cystic teratoma 30.5 KRT7 KRT20 CDX2
12 megacolon 30.4 RET NRTN GDNF EDNRB EDN3 CFTR
13 hydronephrosis 30.4 KRT7 GATA4 FLNA CRP
14 intrahepatic cholangiocarcinoma 30.3 KRT7 KRT20 CDX2
15 adenoma 30.2 SLC26A3 RET KRT7 KRT20 CDX2
16 ovarian germ cell teratoma 30.2 RET KRT7
17 lung disease 30.2 RET FLNA CRP CFTR CD8A
18 appendix adenocarcinoma 30.2 KRT7 KRT20 CDX2
19 jejunal adenocarcinoma 30.2 KRT7 KRT20 CDX2
20 cholangiocarcinoma 30.2 MTOR KRT7 KRT20 CDX2
21 mucinous adenocarcinoma 30.2 KRT7 KRT20 CDX2
22 horseshoe kidney 30.2 KRT7 KRT20 CDX2
23 duodenum cancer 30.2 KRT7 KRT20 CDX2
24 signet ring cell adenocarcinoma 30.2 KRT7 KRT20 CDX2
25 vesicoureteral reflux 1 30.1 RET GDNF CRP
26 disease by infectious agent 30.1 NOD2 CRP CFTR CD8A
27 cholangitis 30.1 NOD2 CRP CFTR
28 patent ductus arteriosus 1 30.1 GATA4 FLNA CRP
29 ovarian brenner tumor 30.1 KRT7 KRT20
30 exanthem 30.1 MTOR CRP CD8A
31 cystitis 30.0 KRT7 KRT20 GDNF CRP
32 neuroendocrine tumor 30.0 RET MTOR KRT20 CDX2
33 respiratory failure 30.0 GATA4 CRP CFTR CD8A ACHE
34 pheochromocytoma 29.9 RET KRT7 GDNF EDN3 CRP
35 meconium ileus 11.6
36 volvulus of midgut 11.3
37 peritonitis 11.2
38 intestinal pseudoobstruction, neuronal, chronic idiopathic, x-linked 11.2
39 ascaris lumbricoides infection 11.1
40 crohn's disease 11.1
41 duodenal atresia 11.1
42 wandering spleen 11.0
43 megacystis-microcolon-intestinal hypoperistalsis syndrome 11.0
44 gastrointestinal defects and immunodeficiency syndrome 11.0
45 hirschsprung disease 2 11.0
46 congenital chloride diarrhea 11.0
47 desmoid tumor 11.0
48 juvenile polyposis syndrome 11.0
49 hirschsprung disease 3 11.0
50 hirschsprung disease 4 11.0

Comorbidity relations with Intestinal Obstruction via Phenotypic Disease Network (PDN): (show top 50) (show all 57)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Pancreatitis
Acute Vascular Insufficiency of Intestine Anxiety
Ascending Colon Cancer Bronchitis
Candidiasis Cecal Benign Neoplasm
Cervical Cancer Chronic Intestinal Vascular Insufficiency
Chronic Kidney Disease Chylomicron Retention Disease
Colorectal Cancer Crohn's Disease
Decubitus Ulcer Deficiency Anemia
Descending Colon Cancer Enterovesical Fistula
Esophageal Disease Esophagitis
Familial Atrial Fibrillation Gastric Cancer
Gastrointestinal System Cancer Generalized Atherosclerosis
Heart Disease Hepatic Flexure Cancer
Hydronephrosis Hypertension, Essential
Hypothyroidism Inflammatory Bowel Disease 1
Intestinal Disease Intestinal Perforation
Iron Deficiency Anemia Irritable Bowel Syndrome
Jejunal Cancer Kidney Disease
Marasmus Neutropenia
Osteoporosis Ovarian Cancer
Pancreatic Cancer Pancreatitis, Hereditary
Paralytic Ileus Peritonitis
Postgastrectomy Syndrome Protein-Energy Malnutrition
Radiation Cystitis Rectosigmoid Junction Neoplasm

Graphical network of the top 20 diseases related to Intestinal Obstruction:



Diseases related to Intestinal Obstruction

Symptoms & Phenotypes for Intestinal Obstruction

UMLS symptoms related to Intestinal Obstruction:


nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

MGI Mouse Phenotypes related to Intestinal Obstruction:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 ACHE CFTR EDN3 EDNRB FLNA GDNF
2 cellular MP:0005384 10.18 CD8A CDX2 EDNRB FLNA GATA4 GDNF
3 digestive/alimentary MP:0005381 10.13 CDX2 CFTR EDN3 EDNRB FLNA GATA4
4 endocrine/exocrine gland MP:0005379 10 CD8A CDX2 CFTR EDNRB GATA4 GDNF
5 growth/size/body region MP:0005378 9.97 ACHE CDX2 CFTR EDNRB FLNA GATA4
6 homeostasis/metabolism MP:0005376 9.83 ACHE CDX2 CFTR CRP EDNRB FLNA
7 mortality/aging MP:0010768 9.53 ACHE CD8A CDX2 CFTR EDN3 EDNRB

Drugs & Therapeutics for Intestinal Obstruction

Drugs for Intestinal Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4 1401-55-4
2
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
3
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
4
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
6
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
7
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
8
Morphine Approved, Investigational Phase 4 57-27-2 5288826
9
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
10
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
11 Neuromuscular Nondepolarizing Agents Phase 4
12 Neuromuscular Blocking Agents Phase 4
13 Gastrointestinal Agents Phase 4
14 Analgesics, Non-Narcotic Phase 4
15 Hormone Antagonists Phase 4
16 glucocorticoids Phase 4
17 Antiemetics Phase 4
18 Hormones Phase 4
19 Antineoplastic Agents, Hormonal Phase 4
20 Adrenergic alpha-Agonists Phase 4
21 Excitatory Amino Acid Antagonists Phase 4
22 Hypnotics and Sedatives Phase 4
23 Adrenergic Agents Phase 4
24 Anesthetics, General Phase 4
25 Anesthetics, Dissociative Phase 4
26 Anesthetics, Intravenous Phase 4
27 Adrenergic Agonists Phase 4
28 Narcotics Phase 4
29 Analgesics Phase 4
30 Anti-Inflammatory Agents Phase 4
31 Anti-Inflammatory Agents, Non-Steroidal Phase 4
32 Anesthetics Phase 4
33 Analgesics, Opioid Phase 4
34 Anesthetics, Local Phase 4
35
Naloxone Approved, Vet_approved Phase 3 465-65-6 5284596
36
lanreotide Approved Phase 3 108736-35-2
37
Metronidazole Approved Phase 3 443-48-1 4173
38
Phenobarbital Approved, Investigational Phase 3 50-06-6 4763
39
Cefuroxime Approved Phase 3 55268-75-2 5361202 5479529
40
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
41
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
42
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
43
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
44 Narcotic Antagonists Phase 3
45 Cola Phase 3
46 Angiopeptin Phase 3
47 Anti-Infective Agents Phase 3
48 Antibiotics, Antitubercular Phase 3
49 Anti-Bacterial Agents Phase 3
50 Antiparasitic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Value of CT-Scan and Oral Gastrografin in the Management of Post Operative Small Bowel Obstruction Completed NCT00389116 Phase 4 gastrograffin;water
2 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Completed NCT01507246 Phase 4 IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
3 Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery Completed NCT02812186 Phase 4 Rocuronium
4 Prospective, Multi-centers, Investigator Sponsored, Randomized Controlled Trial Towards Identifying the Effect of Somatostatin Treatment in Early Postoperative Simple Small Bowel Obstruction Completed NCT01082627 Phase 4 Somatostatin
5 Gastrografin Use in Small Bowel Obstruction Caused by Adherences Completed NCT00601809 Phase 4 Gastrografin®: G
6 Phase 4 Evaluation of SurgiWrapTM to Minimize Soft Tissue Attachment & Reduce the Incidence of Early Post-Operative Bowel Obstruction in Colorectal Surgery Completed NCT00531739 Phase 4
7 The Effects of Preoperative High-dose Dexamethasone on Inflammatory Response and Recovery After Emergency Laparotomy, a Randomized, Double-blind, Placebo-controlled Clinical Trial - AHA STEROID TRIAL Recruiting NCT04791566 Phase 4 Dexamethasone 1 mg/kg;Physiologic saline
8 Ketofol vs Dexmedetomidine for Preventing Post-operative Delirium in Elderly Patients Undergoing Intestinal Obstruction Surgeries. A Randomized Controlled Study Recruiting NCT04816162 Phase 4 ketofol;dexmedetomidine
9 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Terminated NCT01507233 Phase 4 IV morphine sulfate;EXPAREL (bupivacaine liposome injectable suspension)
10 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Open Colectomy Terminated NCT01507220 Phase 4 morphine sulfate;bupivacaine liposome extended-release injectable suspension
11 A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy) Terminated NCT02058290 Phase 4 IV morphine sulfate or Sponsor-approved equivalent;EXPAREL
12 The Use of Gastrografin to Help Alleviate Bowel Obstruction Related to Poor Bowel Motility in Gastroschisis Patients. Withdrawn NCT03334578 Phase 4 Gastrografin
13 Prospective Multicenter Trial for Anti-adhesion Effect of GUARDIX-SGⓇ Following Radical Gastrectomy in Patients With Gastric Cancer. Unknown status NCT02198898 Phase 3
14 Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers: A Randomised Trial Unknown status NCT00164879 Phase 3
15 A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase IIB Study of Oral Naloxone for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-malignant Pain or Malignant Pain Unknown status NCT00020605 Phase 3 naloxone hydrochloride
16 Phase III, Multicentre, Randomised, Double-blind, Comparative Study to Assess the Efficacy and Safety of Lanreotide 30 mg Versus Placebo as a Palliative Treatment of Clinical Symptoms Associated With Intestinal Obstruction Due to Peritoneal Carcinomatosis in Inoperable Patients. Completed NCT00216372 Phase 3 Lanreotide (microparticle formulation)
17 Outcome of Palliative Management of Malignant Large Bowel Obstruction With Colorectal Stents or Surgery Completed NCT00140868 Phase 3
18 Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting Completed NCT01834430 Phase 3
19 Endoscopic Stenting and Elective Surgery Versus Emergency Surgery for Left-sided Malignant Colonic Obstruction: A Prospective Randomized Trial. Completed NCT00758186 Phase 3
20 Phase 3 Study of Antibiotic Prophylaxis Use Prior Emergent Surgery, Because of Acute Appendicitis Completed NCT01524081 Phase 3 Metronidazole, Cefuroxime;Amoxicillin (+ clavulanic acid) and Fluconazole;Placebo;Placebo
21 Bioresorbable Membrane to Reduce Postoperative Small Bowel Obstruction in Patients With Gastric Cancer. A Randomized Clinical Trial Completed NCT00529412 Phase 3
22 The Therapeutic Role of Gastrografin for Treating Small Bowel Obstruction in Children: A Multi-Centre Canadian Prospective Study Recruiting NCT03573921 Phase 2, Phase 3 Gastrografin
23 A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in the Prevention of Acute Enteritis in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy Withdrawn NCT01473290 Phase 3
24 Prospective Study to Assess the Efficacy and Safety of Lanreotide 120 mg as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients Completed NCT01076803 Phase 2 Lanreotide (acetate)
25 An International, Multicentric, Prospective, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 MG Associated to Standard of Care in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction Completed NCT02275338 Phase 2 Lanreotide Autogel
26 Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis Completed NCT00332696 Phase 2 Octreotide LAR;Octreotide (Immediate release);methylprednisolone;Placebo
27 A Pilot Phase I/II Trial of Enteral Wallstents for Colonic Obstruction in the Setting of Malignancy Completed NCT00004911 Phase 1, Phase 2
28 A Pilot Phase I/II Trial of Enteral Wallstents for Duodenal Obstruction in the Setting of Malignancy Completed NCT00004910 Phase 1, Phase 2
29 Octreotide for Palliation of Inoperable Bowel Obstruction: A Phase II Study Completed NCT00004895 Phase 2 octreotide acetate
30 Palliative Management of Inoperable Malignant Bowel Obstruction: A Prospective, Open Label, Phase-2 Study at an NCI Comprehensive Cancer Center Recruiting NCT04027348 Phase 2 Dexamethasone;Metoclopramide;Octreotide
31 A Phase II, Multicentre, Randomized Controlled Study Evaluating The Quality Of Life In Patients With Inoperable Malignant Bowel Obstruction Treated With Lanreotide Autogel 120 mg in Combination With Standard Care vs. Standard Care Alone (QOL IN IMBO STUDY) Terminated NCT02365584 Phase 2 lanreotide (Autogel formulation)
32 Phase I/II Trial of Best Supportive Care and Chemotherapy, Either Cisplatin or Paclitaxel, in Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Presenting With Inoperable Malignant Bowel Obstruction Terminated NCT01083537 Phase 1, Phase 2 Cisplatin;Paclitaxel
33 Prospective, Randomized Trial Comparing Early Laparoscopic Enterolysis Versus a Time-limited Trial of Nonoperative Management for High-grade Small Bowel Obstruction Terminated NCT02692638 Phase 2
34 Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects Completed NCT01596777 Phase 1 Loperamide;Loperamide placebo;Methylnaltrexone placebo;Methylnaltrexone 12 mg sc.;Methylnaltrexone IR capsule;Methylnaltrexone ER capsule;Sulfasalazine
35 Effects of Extended Release Methylnaltrexone Bromide (150 mg b.i.d.) in Comparison to Extended Release Naloxone Hydrochloride (20 mg b.i.d.) on Loperamide-induced Delay of the Oro-cecal, Whole-gut and Colon Transit Time in Healthy Subjects. Completed NCT01596764 Phase 1 Loperamide placebo;Loperamide;Sulfasalazine;Placebo of MNTX and NLX;Naloxone;Methylnaltrexone
36 Therapeutic Oxygen for Gastrointestinal Atony (TOGA): Pilot Trial - Management of Acute Colonic Pseudo-Obstruction With Oxygen Supplementation Completed NCT03386136 Phase 1 100% Oxygen
37 Comparison of Early Operative Treatment (12 h) and 48 h Conservative Treatment in Acute Small Bowel Obstruction Unknown status NCT03139149
38 Prospective Multicenter Validation of a Clinicoradiological Score for Predicting the Severity of Strangulated Small Bowel Occlusion Unknown status NCT01125280
39 Hypertonic Saline 3% Compared to Hypertonic Saline 1.8% for Fluid Management of Intestinal Obstruction Surgery Unknown status NCT03741257 Hypertonic saline
40 Mechanical Bowel Prep and Prophylactic Oral Antibiotic Use in Children: Implications for Intestinal Surgery Complications Unknown status NCT03593252 Senna;Sodium Picosulfate, Magnesium Oxide and Citric Acid;Erythromycin;Kanamycin;Cefazolin;Metronidazole
41 Laparoscopic Versus Open Adhesiolysis for Small Bowel Obstruction - A Multicenter, Prospective, Randomized, Controlled Trial Unknown status NCT01867528
42 Prospective Nationwide Audit of the Management of Adhesive Small Bowel Obstruction: a Snapshot Study Unknown status NCT03786159
43 The Use of Gastrografin in Chronic Radiation Enteropathy With Small Bowel Obstruction:A Retrospective Study Unknown status NCT03642288 Gastrografin
44 A Feasibility Study of Elemental Diet as an Alternative to Parenteral Nutrition for Patients With Inoperable Malignant Bowel Obstruction Unknown status NCT03150992
45 Intrabdominal Pressure in Small Bowel Obstruction as a Possible Predictor for the Need of Operation Unknown status NCT01934283
46 Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients Unknown status NCT01669044 dexmedetomidine;propofol
47 Ultrasound Emergency Diagnosis of Small Bowel Obstruction. An Observational Study Unknown status NCT03226665
48 Colonic Stenting With Elective Surgery Versus Emergency Surgery in the Management of Acute Malignant Colonic Obstruction: a Multicentre, Prospective, Open Label, Cohort Study Unknown status NCT01997684
49 The Impact of Small Bowel Obstruction (SBO) on Quality of Life (QOL); the Efficacy of a Manual Physical Therapy to Improve QOL in Subjects With a History of SBO Unknown status NCT02639195
50 Evaluation of RightBio Metrics', RightSpot pH Indicator, for Rapid Bedside Verification of Proper Nasogastric/ Orogastric Tube Placement in Emergency Department & Intensive Care Unit Patients Unknown status NCT01561729

Search NIH Clinical Center for Intestinal Obstruction

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Heavy mineral oil
Mineral Oil
Mineral Oil, Light
MINERAL OIL,EXTRA HEAVY
MINERAL OIL,MEDIUM
MINERAL OIL,REFINED

Cochrane evidence based reviews: intestinal obstruction

Genetic Tests for Intestinal Obstruction

Genetic tests related to Intestinal Obstruction:

# Genetic test Affiliating Genes
1 Intestinal Obstruction 29

Anatomical Context for Intestinal Obstruction

MalaCards organs/tissues related to Intestinal Obstruction:

40
Colon, Small Intestine, Pancreas, Appendix, Spleen, Uterus, Lymph Node

Publications for Intestinal Obstruction

Articles related to Intestinal Obstruction:

(show top 50) (show all 11812)
# Title Authors PMID Year
1
The comparison of accuracy and practicability between ultrasound and spiral CT in the diagnosis of intestinal obstruction: A protocol for systematic review and meta-analysis. 61 42
33530165 2021
2
Update on SLC26A3 mutations in congenital chloride diarrhea. 6
21394828 2011
3
Effect of laser acupuncture on adhesive small bowel obstruction: A prospective double-blind randomized controlled trial. 42
33655978 2021
4
Propensity score-matched comparison of stenting as a bridge to surgery and emergency surgery for acute malignant left-sided colonic obstruction. 42
33743658 2021
5
Animal models of chronic lung infection with Pseudomonas aeruginosa: useful tools for cystic fibrosis studies. 54 61
18782827 2008
6
Impact of nutrition on phenotype in CFTR-deficient mice. 61 54
17805210 2007
7
Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. 54 61
17030173 2006
8
Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared with their littermate controls. 54 61
16418321 2006
9
Distal intestinal obstruction syndrome in adults with cystic fibrosis. 54 61
15181619 2004
10
Liver cirrhosis and portal hypertension in cystic fibrosis. 61 54
14501614 2003
11
Gdnf haploinsufficiency causes Hirschsprung-like intestinal obstruction and early-onset lethality in mice. 61 54
11774071 2002
12
Cellular localization of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. 54 61
10959824 2000
13
[Gastrointestinal complications of adult patients with cystic fibrosis]. 61 54
10494610 1999
14
Clinical and genetic risk factors for cystic fibrosis-related liver disease. 54 61
9917439 1999
15
Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. 54 61
8589719 1996
16
A case report of inverted Meckel's diverticulum. 61
33732404 2021
17
A Nationwide Survey Study on Medical Student Experience in Acute Care Surgery. 61
33429223 2021
18
Annular pancreas mimicking hypertrophic pyloric stenosis in a female infant. 61
33537107 2021
19
Intestinal obstruction with oral pigmentation: a clue to Peutz-Jeghers syndrome. 61
33795267 2021
20
Recent advances in chemistry and bioactivity of Sargentodoxa cuneata. 61
33460761 2021
21
Abdominal cocoon: precipitated by laparoscopic gas insufflation. 61
33811094 2021
22
Shortening and Plication of Entero-enterostomy for Intussusception in Roux-en-Y Gastric Bypass: Video Report. 61
33512701 2021
23
Spontaneous rupture of sac in bochdalek hernia leading to acute intestinal obstruction. 61
33642409 2021
24
Gastrointestinal symptoms as the first manifestation of antiphospholipid syndrome. 61
33794795 2021
25
Mortality after abdominal emergency surgery in nonagenarians. 61
31664466 2021
26
Endoscopic ultrasonography (EUS) -guided visceral anastomoses: indications and techniques. 61
33793153 2021
27
Complications after bariatric surgery: A multicentric study of 11,568 patients from Indian bariatric surgery outcomes reporting group. 61
32964881 2021
28
Recurrent sigmoid volvulus: Cause of colon perforation, sepsis, and fetal death. 61
33749071 2021
29
Caecal volvulus on a background of recurrent caecocolic torsion. 61
33682464 2021
30
Case-report: A rare cause of intestinal obstruction in late pregnancy. 61
33431333 2021
31
How can we improve perinatal care in isolated multiple intestinal atresia? A retrospective study with a 30-year literature review. 61
33674188 2021
32
Surgical Management of Metastatic Gastrointestinal Stromal Tumors. 61
33743084 2021
33
Supernumerary Remnant Vas Deferens Like Wolffian-Derivatives in a Young Child With Abdominal Cocoon Syndrome-A Clinicopathological Novelty. 61
33749382 2021
34
Gastrointestinal manifestations in COVID-19. 61
33728439 2021
35
A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases. 61
32436120 2021
36
Continuous wound infusion with ropivacaine alone provides adequate analgesia following laparotomy. 61
33409581 2021
37
Small bowel obstruction caused by massive fibroids. 61
33041139 2021
38
Efficacy and safety of short duration radiotherapy combined with chemotherapy for advanced rectal cancer. 61
33728296 2021
39
A Comparison of Perioperative Outcomes, Readmission, and Reoperation for Sacrospinous Ligament Fixation, Uterosacral Ligament Suspension, and Minimally Invasive Sacrocolpopexy. 61
33620894 2021
40
Multiple Site SBRT in Pediatric, Adolescent, and Young Adult Patients With Recurrent and/or Metastatic Sarcoma. 61
33405479 2021
41
Ileocolic intussusception due to intestinal lipoma in an adult patient. 61
33768881 2021
42
Intestinal obstruction secondary to jejunal intussusception in an adult. 61
32988643 2021
43
NOX5 is expressed aberrantly but not a critical pathogenetic gene in Hirschsprung disease. 61
33784990 2021
44
Fibromuscular dysplasia of mesenteric arteries: a rare cause of multiple bowel resections-a case report and literature review. 61
33752607 2021
45
Hiatal Hernia with Acute Obstructive Symptoms After Minimally Invasive Oesophagectomy. 61
32710135 2021
46
When is the right time to take an emergency surgery decision in Mechanical Intestinal Obstruction? 61
33712329 2021
47
Low-dose CT for diagnosing intestinal obstruction and pneumoperitoneum; need for retakes and diagnostic accuracy. 61
33786202 2021
48
Intestinal obstruction in a virgin abdomen: a surgical trompe l'œil. 61
32767811 2021
49
WANDERING LIVER AS A CAUSE OF INTESTINAL OBSTRUCTION. 61
33744365 2021
50
Case report--mechanical bowel obstruction with appendicitis without strangulation and leukocytosis. 61
33643650 2021

Variations for Intestinal Obstruction

ClinVar genetic disease variations for Intestinal Obstruction:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 SLC26A3 NM_000111.3(SLC26A3):c.1000G>T (p.Glu334Ter) SNV Pathogenic 978618 GRCh37: 7:107423769-107423769
GRCh38: 7:107783324-107783324
2 SLC26A3 NM_000111.3(SLC26A3):c.269_270dup Duplication Pathogenic 55994 rs386833476 GRCh37: 7:107434187-107434188
GRCh38: 7:107793742-107793743
3 ERF NM_006494.4(ERF):c.1636C>T (p.Arg546Ter) SNV Uncertain significance 599007 rs764412749 GRCh37: 19:42752628-42752628
GRCh38: 19:42248476-42248476
4 GATA4 NM_002052.5(GATA4):c.94G>C (p.Ala32Pro) SNV Uncertain significance 599008 rs773545065 GRCh37: 8:11565915-11565915
GRCh38: 8:11708406-11708406

Expression for Intestinal Obstruction

Search GEO for disease gene expression data for Intestinal Obstruction.

Pathways for Intestinal Obstruction

GO Terms for Intestinal Obstruction

Biological processes related to Intestinal Obstruction according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.92 NOD2 GDNF EDNRB EDN3 CDX2
2 nervous system development GO:0007399 9.91 RET NRTN GDNF EDNRB ACHE
3 positive regulation of cell differentiation GO:0045597 9.61 GDNF EDN3 CDX2
4 positive regulation of potassium ion transmembrane transport GO:1901381 9.54 FLNA EDN3
5 membrane hyperpolarization GO:0060081 9.49 SLC26A3 CFTR
6 intestinal epithelial cell differentiation GO:0060575 9.48 GATA4 CDX2
7 positive regulation of neuron maturation GO:0014042 9.46 RET MTOR
8 positive regulation of prostaglandin-endoperoxide synthase activity GO:0060585 9.4 NOD2 EDN3
9 intracellular pH elevation GO:0051454 9.37 SLC26A3 CFTR
10 vasoconstriction GO:0042310 9.33 EDNRB EDN3 CRP
11 vein smooth muscle contraction GO:0014826 9.32 EDNRB EDN3
12 posterior midgut development GO:0007497 9.26 RET EDNRB
13 enteric nervous system development GO:0048484 9.13 RET GDNF EDNRB
14 neural crest cell migration GO:0001755 9.02 RET NRTN GDNF EDNRB EDN3

Molecular functions related to Intestinal Obstruction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glial cell-derived neurotrophic factor receptor binding GO:0030116 8.62 NRTN GDNF

Sources for Intestinal Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....